What do systematic reviews say?

Abundant water intake vs no treatment

The review found no eligible studies for this question.

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sleeping in darkness vs no treatment

The review found no eligible studies for this question.

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Specially processed cereals vs placebo

The review found no eligible studies for this question.

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Ventilation tubes vs no treatment

The review found no eligible studies for this question.

• Surgical interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Endolymphatic sac decompression vs placebo (sham surgery)

The review found no eligible studies for this question.

• Surgical interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dietary intervention (probiotics) vs placebo

The review found no eligible studies for this question.

• Non‐pharmacological interventions for prophylaxis of vestibular migraine 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

CBT vs no treatment

The review found no eligible studies for this question.

• Non‐pharmacological interventions for prophylaxis of vestibular migraine 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Triptans vs placebo

• Pharmacological interventions for acute attacks of vestibular migraine 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 114 participants
  Very low

Vestibular rehabilitation vs placebo or no treatment

The review found no eligible studies for this question.

• Non‐pharmacological interventions for persistent postural‐perceptual dizziness (PPPD) 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

tDCS vs placebo

• Non‐pharmacological interventions for persistent postural‐perceptual dizziness (PPPD) 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 21 participants
  Very low

Talking therapies or stress management vs placebo or no treatment

The review found no eligible studies for this question.

• Non‐pharmacological interventions for persistent postural‐perceptual dizziness (PPPD) 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Palmitoylethanolamide and luteolin vs no intervention

• Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 12 participants
  Very low

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

• Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 18 participants
  Very low

Intranasal steroid spray vs placebo or no intervention

• Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 77 participants
  Very low

IM erythropoietin vs oral placebo

The review found no eligible studies for this question.

• Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Rituximab vs cyclophosphamide

Rituximab showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.11 [0.72, 1.71]
  2 studies · 241 participants
  Moderate

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.25
  1 study · 140 participants
  Low

Azathioprine vs cyclophosphamide

Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.18 [0.45, 3.07]
  1 study · 144 participants
  Moderate

CBT with therapist support vs fatigue information leaflet only

The review found no eligible studies for this question.

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Physical activity advice plus omega 3 vs no physical activity advice plus omega 3

The review found no eligible studies for this question.

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found